Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results Conference Paper uri icon


  • Voskoboynik, M
  • Mileshkin, L
  • Gan, Hui
  • Millward, M
  • Au-Yeung, G
  • Meniawy, TM
  • Kichenadasse, G
  • Zhang, K
  • Zhang, M
  • Mu, S
  • Lickliter, JD

publication date

  • 2019